Kayla Merritt
Family · Jackson, GANPI 1770986697
Payments from drug & device makers
Across 503 payments — averaging $18.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Amgen$647
- Xeris Pharmaceuticals, Inc.$524
- Sanofi-aventis U.S. LLC$514
- Corcept Therapeutics$383
- plus $5K from 38 others
Across 1 payment — averaging $50.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$50
What the payments were for
- Food & beverage$9,502100%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UNITY DIABETES MANAGEMENT SYSTEM$294
- GVOKE PFS$233
- Ozempic$125
- TEPEZZA$122
- MINIMED 780G$121
How this compares
$9,523 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 420 | $790,081 |
| MounjaroTirzepatide | 178 | $261,437 |
| JardianceEmpagliflozin | 149 | $214,732 |
| TrulicityDulaglutide | 136 | $198,041 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 111 | $146,795 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $131,272 |
| Tresiba Flextouch U-200Insulin Degludec | 106 | $116,767 |
| FarxigaDapagliflozin Propanediol | 98 | $103,242 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 59 | $69,153 |
| JanuviaSitagliptin Phosphate | 52 | $62,463 |
| Tresiba Flextouch U-100Insulin Degludec | 87 | $59,602 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 38 | $55,088 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 45 | $46,378 |
| Novolog FlexpenInsulin Aspart | 114 | $29,968 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 32 | $24,438 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog, Fiasp | $1,341 | $819,823478 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,414 | $474,444377 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $158 | $317,029239 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $514 | $146,795111 claims |
| AstraZenecaFarxiga | $312 | $103,24298 claims |
| AbbVieSynthroid | $352 | $16,291184 claims |
| Cequr CorporationCequr Simplicity | $135 | $13,45417 claims |
| BayerKerendia | $228 | $11,35711 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $207 | $3,797349 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Jackson
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.